TABLE 9.

Susceptibilities of C. krusei, C. inconspicua, and C. norvegensis to fluconazole and voriconazole by specimen typea

Specimen type/site (total no. of isolates)Antifungal agentC. kruseiC. inconspicuaC. norvegensis
No. of isolates tested% RbNo. of isolates tested% RNo. of isolates tested% R
Blood (20,704)Fluconazole45974.52437.5137.7
Voriconazole4598.5244.2130.0
NSBF (8,650)Fluconazole24680.54551.11855.6
Voriconazole2434.5454.4180.0
Urine (25,881)Fluconazole51880.12653.82356.5
Voriconazole51611.4267.7238.7
Respiratory tract (56,961)Fluconazole1,78779.223151.56442.2
Voriconazole1,7607.82292.2631.6
Skin/soft tissue (11,221)Fluconazole25281.72326.1238.7
Voriconazole2518.0234.3230.0
Genital tract (44,839)Fluconazole56671.96262.91952.6
Voriconazole5536.9624.8190.0
Miscellaneous NOS (33,397)Fluconazole1,25179.215558.78843.2
Voriconazole1,2235.81545.2888.0
  • a Isolates were obtained from 133 institutions.

  • b % R, percent resistant (zone diameter, ≤14 mm [fluconazole] and ≤13 mm [voriconazole]).